Develops cannabinoid-based therapies for central nervous system disorders and respiratory conditions, aiming to leverage the therapeutic potential of cannabinoids.
Incannex Healthcare Limited, formerly known as Impression Healthcare Limited, specializes in the research, development, and commercialization of medicinal cannabinoid and psychedelic pharmaceutical products in Australia. The company's diverse product portfolio includes ultrapure tetrahydrocannabinol (APIRx-1801), cannabidiol (APIRx-1802), and cannabigerol (APIRx-1803), targeting various therapeutic applications.
Incannex Healthcare has advanced several compounds through clinical trials, such as IHL-42X for obstructive sleep apnea and Psi-GAD for generalized anxiety disorder, both in Phase IIa. Additionally, their pipeline includes MedChew Dronabinol for chemotherapy-induced nausea, CanChew Plus for irritable bowel syndrome, and several formulations addressing conditions like vitiligo, psoriasis, and atopic dermatitis.
Founded in 2001 and headquartered in Melbourne, Australia, Incannex Healthcare continues to expand its pre-clinical trials for products like IHL-675A for inflammatory lung disease and rheumatoid arthritis, MedChew formulations for pain management in multiple sclerosis, and novel treatments for conditions such as Parkinson's disease, dementia, and restless legs syndrome. The company remains committed to advancing innovative cannabinoid and psychedelic therapies to address unmet medical needs globally.